Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

JOINN LABORATORIES (CHINA) CO., LTD.

北 京 昭 衍 新 藥 研 究 中 心 股 份 有 限 公 司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6127)

2021 FIRST QUARTERLY REPORT

This announcement is made pursuant to Rule 13.09(2) and Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The following is the first quarterly report of JOINN Laboratories (China) Co., Ltd. (the "Company", together with its subsidiaries, collectively the "Group") for financial year 2021 (the "2021 First Quarterly Report"). This announcement and the accompanying financial statements are originally prepared in Chinese and published in both English and Chinese. If there is any inconsistency or conflict between the Chinese and English versions, the Chinese version shall prevail.

Shareholders of the Company and public investors should note that the financial report therein is prepared in accordance with the PRC Accounting Standards for Business Enterprises and has not been audited.

By order of the Board

JOINN Laboratories (China) Co., Ltd.

Feng Yuxia

Chairperson

Hong Kong, Thursday, April 29, 2021

As at the date of this announcement, the Board comprises Ms. FENG Yuxia as the Chairperson and executive Director, Mr. ZUO Conglin, Mr. GAO Dapeng, Ms. SUN Yunxia, Dr. YAO Dalin as executive Directors, Mr. GU Xiaolei as a non-executive Director, and Mr. SUN Mingcheng, Dr. ZHAI Yonggong, Mr. OU Xiaojie and Mr. ZHANG Fan as independent non-executive Directors.

- 1 -

  1. Important Notice
  1. The Board of Directors (the "Board"), the Supervisory Committee and the Directors, Supervisors and Senior Management of the Company warrant the truthfulness, accuracy and completeness of the contents of the Quarterly Report and that there are no false information, misleading statements or material omissions in the quarterly report, and shall assume several and joint legal responsibilities.
  2. All Directors of the Company attended the Board meeting to review the quarterly report.
  3. Feng Yuxia, the legal representative of the Company, Yu Aishui, the chief financial officer and Yu Aishui, the director of the accounting department warrant the truthfulness, accuracy and completeness of the financial statements in this quarterly report.
  4. The First Quarterly Report of the Company has not been audited.

II.

Company Profile

2.1

Major financial data

Unit: RMB

Currency: RMB

As at the end of

Increase/

the Reporting

As at the end of

decrease

Period

the previous year

(%)

Total assets

7,633,988,121.93

2,107,821,636.06

262.17

Net assets attributable to

shareholders of the Company

6,597,313,422.62

1,224,899,092.29

438.60

From the

From the

beginning of

beginning of

the year to

the previous year

the end of

to the end of

Increase/

the Reporting

the last reporting

decrease

Period

period

(%)

Net cash flow from operating

activities

34,482,082.76

34,315,183.44

0.49

- 2 -

From the

From the

beginning of

beginning of

the year to

the previous year

the end of

to the end of

Increase/

the Reporting

the last reporting

decrease

Period

period

(%)

Revenue

200,992,535.41

154,713,623.00

29.91

Net profit attributable to

shareholders of the Company

93,357,265.26

19,127,779.80

388.07

Net profit attributable to

shareholders of the Company

after deducting non-recurring

gain or loss items

79,434,821.17

14,761,153.59

438.13

Weighted average return on

Increased by 0.80

equity (%)

3.08

2.28

percentage point

Basic earnings per share (RMB

per share)

0.39

0.09

333.33

Diluted earnings per share

(RMB per share)

0.38

0.09

322.22

Note: The Company completed its listing of H shares on February 26, 2021 and raised proceeds of HK$6.373 billion (including the exercise of over-allotment options). The effect on the net profit of the exchange gain incurred during the current period was RMB57,887,235.16. Excluding such effect, the growth rate of the net profit attributable to the shareholders of the listed company was 85.44% and the growth rate of the net profit attributable to the shareholders of the listed company (excluding non-recurring gains or losses) was 45.97%.

- 3 -

Non-recurring gain on loss items and amounts

  • Applicable □ Not applicable

Unit: RMB Currency: RMB

Amount for

Item

the Reporting

Period

Description

Gain or loss on disposal of non-current

assets

-4,468.47

Tax refunds or relief subject to ultra vires

or without official approval

Government grants included in profit or

loss of the current period (except for

those closely related to the Company's

normal operation and which were granted

on a recurring basis subject to certain

amount or volume upon fulfilment of

specific standards in compliance with the

government policies and regulations)

17,220,308.10

Capital occupancy fee from non-financial

enterprises recognized through profit or

loss for the period

Gain from the difference between the

cost of investment on the subsidiaries,

associates and joint ventures and the

shared fair value of identifiable net assets

of the investee

Profit or loss from exchange of non-

monetary assets

Gain or loss from entrusted investments or

assets management

Provision for impairment of assets due to

force majeure such as natural disasters

Profit or loss from debt restructuring

Corporate restructuring costs, such as

employee placement expenses and

integration costs

Profit or loss representing the difference

between the unfair transaction

consideration and the fair value of the

transaction

- 4 -

Amount for

Item

the Reporting

Period

Description

Net profit or loss of subsidiaries resulting

from merger of enterprises under

common control from the beginning of

the current period to the date of merger

Profit or loss from contingencies not

related to the ordinary operations of the

Company

Investment incomes from holding financial

assets available-for-trading, derivative

financial assets, changes in the fair

value from trading financial liabilities

and derivative financial liabilities,

disposals of trading financial assets,

derivative financial assets, trading

financial liabilities, derivative financial

liabilities and investment in other equity

instruments, except for effective hedging

business related to normal operating of

the Company

1,427,975.33

Reversal of the provisions for impairment

of receivables and contract assets subject

to impairment test separately

Profit or loss from external entrusted loans

Profit or loss from changes in fair value of

investment properties using the fair value

model for subsequent measurement

One-off adjustment to profit or loss for

the current period in accordance with

laws and regulations on taxation and

accounting

Fees income from custodian business

Other non-operating incomes and expenses

other than the above items

-3,763,024.97

Other profit or loss items falling within the

meaning of non-recurring profit or loss

Impact of non-controlling interests

(after tax)

Effect of income tax

-958,345.90

Total

13,922,444.09

- 5 -

2.2 Total number of Shareholders and shareholding of top 10 Shareholders and top 10 holders of tradable shares (or Shareholders holding Shares not subject to trading restrictions) as at the end of the Reporting Period

Unit: share

Total number of Shareholders

21,198

Shareholding of top 10 Shareholders

Number of

Shares held as

Number of

at the end of

Shares subject

Pledged or frozen Shares

the Reporting

Percentage

to trading

Nature of

Full name of shareholder

Period

(%)

restrictions

Status

Number

Shareholder

Feng Yuxia

64,073,468

23.66%

0

Nil

0

Domestic natural

person

HKSCC NOMINEES

43,359,499

16.01%

0

Nil

0

Overseas legal

LIMITED

entity

Zhou Zhiwen

34,568,986

12.76%

0

Nil

0

Domestic natural

person

Gu Xiaolei

16,078,455

5.94%

0

Pledged

5,600,000

Domestic natural

person

Hong Kong Securities

12,802,584

4.73%

0

Nil

0

Overseas legal

Clearing Company Limited

entity

Gu Meifang

11,008,078

4.06%

0

Pledged

8,720,000

Domestic natural

person

Zuo Conglin

9,900,032

3.66%

31,976

Pledged

2,305,000

Domestic natural

person

National Social Security

5,768,878

2.13%

0

Nil

0

Others

Fund (Combination 406)

Industrial and Commercial

2,643,360

0.98%

0

Nil

0

Others

Bank of China Limited -

China-Europe Medical and

Health Hybrid Securities

Investment Fund

China Construction Bank

2,300,000

0.85%

0

Nil

0

Others

Corporation Fund

(中國建設銀行股份有限公

司－工銀瑞信前沿醫療股

票型證券投資基金)

- 6 -

Shareholdings of top 10 holders of Shares not subject to trading restrictions

Number of

Shares not

Class and number of shares

subject to

Name of shareholder

trading

restrictions

Class

Number

Feng Yuxia

64,073,468

RMB-denominated

64,073,468

ordinary shares

HKSCC NOMINEES LIMITED

43,359,499

Overseas-listed

43,359,499

foreign shares

Zhou Zhiwen

34,568,986

RMB-denominated

34,568,986

ordinary shares

Gu Xiaolei

16,078,455

RMB-denominated

16,078,455

ordinary shares

Hong Kong Securities Clearing

12,802,584

RMB-denominated

12,802,584

Company Limited

ordinary shares

Gu Meifang

11,008,078

RMB-denominated

11,008,078

ordinary shares

Zuo Conglin

9,868,056

RMB-denominated

9,868,056

ordinary shares

National Social Security Fund

5,768,878

RMB-denominated

5,768,878

(Combination 406)

ordinary shares

Industrial and Commercial Bank of

2,643,360

RMB-denominated

2,643,360

China Limited - China-Europe

ordinary shares

Medical and Health Hybrid

Securities Investment Fund

China Construction Bank

2,300,000

RMB-denominated

2,300,000

Corporation Fund (中國建設銀行

ordinary shares

股份有限公司－工銀瑞信前沿醫

療股票型證券投資基金)

Description of connected

1. Feng Yuxia and Zhou Zhiwen are in a spousal

relationships or concerted actions

relationship; 2. Gu Meifang and Gu Xiaolei are aunt and

of the above Shareholders

nephew. Except from this, the Company is not aware of

any related party relationship among the shareholders

mentioned above, and not aware of whether they are

parties acting in concert.

Description of preference

Nil

shareholders with voting rights

restored and their shareholdings

Note: HKSCC NOMINEES LIMITED holds shares on behalf of multiple customers.

- 7 -

2.3 Total number of preference Shareholders and shareholdings of top 10 preference Shareholders and top 10 preference Shareholders not subject to trading restrictions as at the end of the Reporting Period

  1. □ Applicable ✓ Not applicable

  2. Significant events

3.1 Significant changes in major financial statement items and financial indicators of the Company and the reasons thereof

✓ Applicable □ Not applicable

3.1.1 Reasons of significant changes in the items in the consolidated balance sheet during the Reporting Period

March 31,

December 31,

Item

2021

2020

Change

Reasons

Cash at bank and

5,657,723,895.31

308,689,959.55

1,732.82%

Mainly due to the

on hand

receipt of raised

proceeds

Bills receivable

3,020,000.00

2,175,000.00

38.85%

Mainly due to the

increase in bills

received

Other receivables

4,764,113.07

8,765,341.77

-45.65%

Mainly due to the

transfer of deposits

of land use rights to

payments

Right-of-use

65,945,902.14

Not

Mainly due to the

assets

applicable

adoption of new

leasing standard

during the current

period

Deferred tax

52,961,740.27

35,261,614.74

50.20%

Mainly due to the

assets

increase in deductible

temporary differences

in relation to share-

based payments due to

the increase in share

price

Other non-current

58,011,580.39

36,232,987.14

60.11%

Mainly due to the

assets

prepayment of land use

right payments

Account payables

80,814,491.38

60,285,553.10

34.05%

Mainly due to the

increase in purchase

during the current

period

- 8 -

March 31,

December 31,

Item

2021

2020

Change

Reasons

Receipts in

1,570,000.00

-100.00%

Mainly due to the

advance

transfer of advance

receipts from

customers to projects

during the current

period

Tax payables

10,849,554.31

25,600,650.35

-57.62%

Mainly due to the

payment of 2020

Enterprise Income

Tax during the current

period

Non-current

17,772,483.59

3,080,988.42

476.84%

Mainly due to the

liabilities due

adoption of new

within one year

leasing standard

during the current

period

Long-term

9,690,467.43

21,375,166.75

-54.66%

Mainly due to the

borrowings

waiver of PPP loan

of Biomere, our

subsidiary

Lease liabilities

49,815,365.10

Not

Mainly due to the

applicable

adoption of new

leasing standard

during the current

period

Capital reserves

5,518,563,086.27

249,804,268.45

2,109.15%

Mainly due to the

listing on the Hong

Kong Stock Exchange

during the current

period

Other

-1,490,556.44

29,063,134.69

-105.13%

Mainly due to the

comprehensive

increase in investment

income

costs of other equity

instruments

Non-controlling

-992,185.95

-734,936.01

Not

Mainly due to the loss

interests

applicable

of holding subsidiaries

- 9 -

3.1.2 Reasons of significant changes in the items in the statement of profit or loss during the Reporting Period

January to

January to

Item

March, 2021

March, 2020

Change

Reason

Revenue

200,992,535.41

154,713,623.00

29.91%

Mainly due to the

increase in business

volume during the

current period

Costs

97,328,314.02

78,798,635.04

23.52%

Mainly due to the

increase in business

volume during the

current period

Taxes and

1,605,433.14

1,116,338.97

43.81%

Mainly due to the

surcharges

increase in business

volume during the

current period

Administration

67,109,647.64

46,013,786.64

45.85%

Mainly due to the

expenses

increase in labor

costs and office

expense

Finance expenses

-67,795,020.99

-456,002.54

Not

Mainly due to the

applicable

exchange gain arising

from the raised

proceeds received

during the current

period

Other income

17,483,886.23

4,572,839.64

282.34%

Mainly due to the

waiver of PPP loan

obtained by Biomere,

our subsidiary

Gains from

902,485.17

-461,656.92

Not

Mainly due to the

changes in fair

applicable

fair value change in

value

biological assets

Credit

-924,776.37

2,284,159.12

-140.49%

Mainly due to the

impairment

provision for credit

losses

impairment losses

during the current

period

Impairment

-1,112,952.02

162,923.96

-783.11%

Mainly due to the

losses

increase in provision

for decline in prices

of inventories during

the current period

- 10 -

January to

January to

Item

March, 2021

March, 2020

Change

Reason

Non-operating

6,705.00

240.00

2,693.75%

Mainly due to the

income

increase in scrap

sales during the

current period

Non-operating

3,774,197.84

436,406.69

764.84%

Mainly due to the

expense

increase in donation

expense during the

current period

Profit before

104,035,964.94

21,934,613.06

374.30%

Mainly due to the

income tax

increase in business

volume during the

current period

Income tax

10,935,949.62

3,146,089.08

247.60%

Mainly due to the

expense

increase in business

volume during the

current period

Net cash flow

-66,686,497.84

-29,737,009.85

Not

Mainly due to the

generated

applicable

net increase in

from investing

investments of wealth

activities

management products

and the increase in

purchase of long-

term assets

Net cash

5,312,443,354.88

1,602,158.28

331,480.43%

Mainly due to the

generated

receipt of raised

from financing

proceeds during the

activities

current period

  1. Analysis and explanations of the progress, impact and solution of significant events
    • Applicable ✓ Not applicable
  3. Undertakings not performed during the Reporting Period
    • Applicable ✓ Not applicable

- 11 -

3.4 Caution and explanation as to the anticipated loss of accumulated net profit from the beginning of the year to the end of the next reporting period or significant changes over the same period of last year

□ Applicable ✓ Not applicable

Company name

Joinn Laboratories (China) Co., Ltd.

Legal Representative

Feng Yuxia

Date

April 29, 2021

IV. Appendix

4.1 Financial statement

Consolidated Balance Sheet

As at March 31, 2021

Prepared by: Joinn Laboratories (China) Co., Ltd.

Unit: RMB

Currency: RMB Type of audit: Unaudited

As at

As at

Item

March 31, 2021

December 31, 2020

Current assets:

Cash at bank and on hand

5,657,723,895.31

308,689,959.55

Balances with clearing companies

Placements with banks and other

financial institutions

Financial assets held for trading

223,543,843.83

238,902,999.99

Derivative financial assets

Bills receivables

3,020,000.00

2,175,000.00

Account receivables

75,154,346.01

88,866,136.10

Receivables financing

Prepayments

42,581,612.38

49,509,582.85

Premium receivables

Reinsurance account receivables

Deposit receivables from reinsurance

contracts

Other receivables

4,764,113.07

8,765,341.77

Including: Interest receivables

Dividend receivables

Financial assets purchased under

agreements to resell

Inventories

519,993,150.90

406,214,711.26

- 12 -

As at

As at

Item

March 31, 2021

December 31, 2020

Contract assets

61,693,088.71

66,812,242.99

Assets held-for-sale

Non-current assets due within one

year

Other current assets

15,654,839.78

12,974,960.25

Total current assets

6,604,128,889.99

1,182,910,934.76

Non-current assets:

Loans and advances to customers

Debt investment

Other debt investment

Long-term receivables

Long-term equity investments

Investments in other equity instruments

64,444,809.52

64,444,809.52

Other non-current financial assets

Investment properties

Fixed assets

447,616,196.82

445,555,655.12

Construction in progress

52,393,262.38

48,633,480.15

Biological assets for breeding

18,130,166.72

19,433,780.68

Oil and gas assets

Right-of-use assets

65,945,902.14

Intangible assets

121,090,988.86

123,631,240.12

Development expenses

Goodwill

126,186,809.43

125,295,803.39

Long-term deferred expenditures

23,077,775.41

26,421,330.44

Deferred tax assets

52,961,740.27

35,261,614.74

Other non-current assets

58,011,580.39

36,232,987.14

Total non-current assets

1,029,859,231.94

924,910,701.30

Total assets

7,633,988,121.93

2,107,821,636.06

Current liabilities:

Short-term borrowings

Borrowings from central bank

Placement from banks and other

financial institutions

Financial liabilities held for treading

Derivative financial liabilities

Bills payables

- 13 -

As at

As at

Item

March 31, 2021

December 31, 2020

Account payables

80,814,491.38

60,285,553.10

Receipts in advance

1,570,000.00

Contract liabilities

689,009,387.93

583,537,351.54

Financial assets sold under

agreements to repurchase

Deposits from customers and banks

Customer deposits for securities

trading

Customer deposits for securities

underwriting

Employee benefit payables

42,398,423.15

49,700,312.39

Tax payables

10,849,554.31

25,600,650.35

Other payables

30,489,542.06

32,997,002.18

Including: Interest payables

Dividend payables

Handling charges and commission

payable

Reinsurance account payables

Liabilities held-for-sale

Non-current liabilities due within one

year

17,772,483.59

3,080,988.42

Other current liabilities

3,786,397.71

3,270,304.53

Total current liabilities

875,120,280.13

760,042,162.51

Non-current liabilities:

Deposits for insurance contracts

Long-term borrowings

9,690,467.43

21,375,166.75

Debenture payables

Including: Preference shares

Perpetual bonds

Lease liabilities

49,815,365.10

Long-term payables

Long-term payroll payables

Projected liabilities

Deferred income

64,318,990.21

67,040,785.16

Deferred tax liabilities

38,721,782.39

35,199,365.36

Other non-current liabilities

Total non-current liabilities

162,546,605.13

123,615,317.27

- 14 -

As at

As at

Item

March 31, 2021

December 31, 2020

Total liabilities

1,037,666,885.26

883,657,479.78

Owners' equity (or shareholders'

equity):

Paid up capital (or share capital)

270,820,329.00

227,454,729.00

Other equity instruments

Including: Preference shares

Perpetual bonds

Capital reserves

5,518,563,086.27

249,804,268.45

Less: Treasury shares

9,915,527.00

9,915,527.00

Other comprehensive income

-1,490,556.44

29,063,134.69

Special reserve

Surplus reserve

59,290,828.07

59,290,828.07

General risks reserve

Retained earnings

760,045,262.72

669,201,659.08

Total owners' equity (or shareholders'

equity) attributable to the parent

company

6,597,313,422.62

1,224,899,092.29

Non-controlling interests

-992,185.95

-734,936.01

Total owners' equity

(or shareholders' equity)

6,596,321,236.67

1,224,164,156.28

Total liabilities and owners'

equity (or shareholders'

equity)

7,633,988,121.93

2,107,821,636.06

Director of

Legal Representative:

Chief Financial Officer:

the Accounting Department:

Feng Yuxia

Yu Aishui

Yu Aishui

- 15 -

Balance Sheet of the Parent Company

As at March 31, 2021

Prepared by: Joinn Laboratories (China) Co., Ltd.

Unit: RMB

Currency: RMB

Audit status: Unaudited

As at

As at

Item

March 31, 2021

December 31, 2020

Current assets:

Cash at bank and on hand

5,415,296,923.30

49,939,882.78

Financial assets held for trading

162,644,747.94

208,003,904.10

Derivative financial assets

Bills receivables

Account receivables

21,978,844.75

7,980,312.02

Receivables financing

Prepayments

30,538,027.44

27,191,935.98

Other receivables

71,453,390.92

55,977,804.58

Including: Interest receivables

Dividend receivables

Inventories

113,374,807.42

103,417,687.78

Contract assets

30,866,884.31

34,223,306.49

Assets held-for-sale

Non-current assets due within one

year

Other current assets

4,257,324.19

3,927,708.06

Total current assets

5,850,410,950.27

490,662,541.79

Non-current assets:

Debt investment

Other debt investment

Long-term receivables

Long-term equity investments

576,140,484.02

549,277,848.74

Investments in other equity

instruments

64,444,809.52

64,444,809.52

Other non-current financial assets

Investment properties

Fixed assets

110,110,052.13

120,373,701.14

Construction in progress

1,973,617.77

2,137,481.93

Biological assets for breeding

Oil and gas assets

Right-of-use assets

2,479,367.08

- 16 -

As at

As at

Item

March 31, 2021

December 31, 2020

Intangible assets

16,636,350.58

17,856,922.01

Development expenses

Goodwill

Long-term deferred expenditures

3,665,173.50

3,672,458.65

Deferred tax assets

18,865,461.06

10,414,065.73

Other non-current assets

3,348,458.76

3,923,902.76

Total non-current assets

797,663,774.42

772,101,190.48

Total assets

6,648,074,724.69

1,262,763,732.27

Current liabilities:

Short-term borrowings

Financial liabilities held for trading

Derivative financial liabilities

Bills payables

Account payables

26,458,752.80

30,898,749.24

Receipts in advance

Contract liabilities

224,890,816.77

194,127,498.08

Employee benefit payables

15,500,952.88

16,783,931.66

Tax payables

2,420,850.42

1,201,325.41

Other payables

37,938,199.24

16,168,322.16

Including: Interests payable

Dividends payable

Liabilities held-for-sale

Non-current liabilities due within one

year

1,391,926.98

Other current liabilities

1,789,923.72

1,452,133.47

Total current liabilities

310,391,422.81

260,631,960.02

Non-current liabilities:

Long-term borrowings

Debenture payables

Including: Preference shares

Perpetual bonds

Lease liabilities

1,452,894.68

Long-term payables

Long-term payroll payables

Projected liabilities

Deferred income

13,771,318.06

14,107,308.34

- 17 -

As at

As at

Item

March 31, 2021

December 31, 2020

Deferred tax liabilities

17,974,359.95

13,885,085.02

Other non-current liabilities

Total non-current liabilities

33,198,572.69

27,992,393.36

Total liabilities

343,589,995.50

288,624,353.38

Owners' equity (or shareholders'

equity):

Paid up capital (or share capital)

270,820,329.00

227,454,729.00

Other equity instruments

Including: Preference shares

Perpetual bonds

Capital reserves

5,504,187,642.69

240,609,043.62

Less: Treasury shares

9,915,527.00

9,915,527.00

Other comprehensive income

12,278,088.09

44,578,088.09

Special reserve

Surplus reserve

59,290,828.07

59,290,828.07

Retained earnings

467,823,368.34

412,122,217.11

Total owners' equity (or

shareholders' equity)

6,304,484,729.19

974,139,378.89

Total liabilities and owners'

equity (or shareholders'

equity)

6,648,074,724.69

1,262,763,732.27

Director of

Legal Representative:

Chief Financial Officer:

the Accounting Department:

Feng Yuxia

Yu Aishui

Yu Aishui

- 18 -

Consolidated Income Statement

January to March 2021

Prepared by: Joinn Laboratories (China) Co., Ltd.

Unit: RMB

Currency: RMB

Audit status: Unaudited

First

First

Item

quarter of

quarter of

2021

2020

I. Total revenue

200,992,535.41

154,713,623.00

Including: Revenue

200,992,535.41

154,713,623.00

Interest income

Premiums earned

Handling charges and

commission income

II. Total cost

111,324,851.53

140,348,068.02

Including: Cost

97,328,314.02

78,798,635.04

Interest expenses

Handling charges and

commission expenses

Payments on surrender

Net claim expenses

Net provision for

insurance contract

reserves

Policyholder dividend

expenses

Reinsurance costs

Taxes and surcharges

1,605,433.14

1,116,338.97

Selling and marketing

expenses

3,197,669.49

3,114,756.43

Administration expenses

67,109,647.64

46,013,786.64

Research and development

expenses

9,878,808.23

11,760,553.48

Finance expenses

-67,795,020.99

-456,002.54

Including: Interest expense

791,416.57

334,689.14

Interest income

432,029.22

420,814.61

- 19 -

First

First

Item

quarter of

quarter of

2021

2020

Add: Other income

17,483,886.23

4,572,839.64

Investment gains

("-" indicating loss)

1,787,131.49

1,449,051.36

Including: Gains from

investment in

associates and

joint ventures

Derecognition

of income from

financial assets

measured at

amortised cost

Exchange gains

("-" indicating loss)

Gains from net

exposure to

hedging ("-" indicating loss)

Gains from changes

in fair value

("-" indicating loss)

902,485.17

-461,656.92

Credit impairment

losses ("-" indicating loss)

-924,776.37

2,284,159.12

Assets impairment

losses ("-" indicating loss)

-1,112,952.02

162,923.96

Gains from disposal

of assets ("-" indicating loss)

-0.60

-2,092.39

III. Operating profit ("-" indicating

loss)

107,803,457.78

22,370,779.75

Add: Non-operating income

6,705.00

240.00

Less: Non-operating expenses

3,774,197.84

436,406.69

- 20 -

First

First

Item

quarter of

quarter of

2021

2020

IV. Profits before income tax ("-"

indicating total losses)

104,035,964.94

21,934,613.06

Less: Income tax expenses

10,935,949.62

3,146,089.08

V. Net profits ("-" indicating net loss)

93,100,015.32

18,788,523.98

(I) Classified by the continuity of operation

1.

Net profit from continuing

operations ("-" indicating net

loss)

93,100,015.32

18,788,523.98

2.

Net profit from discontinued

operations ("-" indicating net

loss)

(II) Classified by the ownership

1.

Net profit attributable to equity

shareholders of the company ("-"

indicating net loss)

93,357,265.26

19,127,779.80

2.

Profit and loss of non-controlling

interests ("-" indicating net loss)

-257,249.94

-339,255.82

VI. Other comprehensive income, net

of tax

-30,711,088.88

3,841,583.45

(I) Other comprehensive income

attributable to owners of the

parent company, net of tax

-30,711,088.88

3,841,583.45

1.

Other comprehensive income that

will not be reclassified to profit or

loss

-32,300,000.00

(1)

Changes in re-measurement of

defined benefit plans

(2)

Other comprehensive income that

will not be transferred to profit or

loss accounted for using equity

method

(3)

Changes in fair value of

investments in other equity

instruments

-32,300,000.00

(4)

Changes in fair value of the

company's own credit risk

- 21 -

First

First

Item

quarter of

quarter of

2021

2020

2. Other comprehensive income that

will be reclassified to profit or loss

1,588,911.12

3,841,583.45

(1)Other comprehensive income that

will be transferred to profit or loss

accounted for using equity method

(2)

Changes in fair value of other debt

investments

(3)

Financial assets reclassified to

other comprehensive income

(4)

Credit impairment allowance of

other debt investments

(5)

Cash flow hedging reserve

(6)

Exchange difference on translation

of foreign financial statements

1,588,911.12

3,841,583.45

(7)

Others

(II) Other comprehensive income

attributable to minority shareholders,

net of tax

VII.Total comprehensive income

62,388,926.44

22,630,107.43

(1)

Total comprehensive income

attributable to equity shareholders

of the parent company

62,646,176.38

22,969,363.25

(2)

Total comprehensive income

attributable to non-controlling

interests

-257,249.94

-339,255.82

VIII.Earnings per share:

(I) Basic earnings per share (RMB

per share)

0.39

0.09

(II) Diluted earnings per share (RMB

per share)

0.38

0.09

For the business combination involving enterprises under common control during the Reporting Period, realised net profit of the merged parties before the merger was RMB0 (corresponding period of the previous year: RMB0).

Director of

Legal Representative:

Chief Financial Officer:

the Accounting Department:

Feng Yuxia

Yu Aishui

Yu Aishui

- 22 -

Income Statement of the Parent Company

January to March 2021

Prepared by: Joinn Laboratories (China) Co., Ltd.

Unit: RMB

Currency: RMB Type of audit: Unaudited

First Quarter of

First Quarter of

Item

2021

2020

I. Revenue

50,746,980.14

39,507,445.16

Less: Cost

29,339,699.35

21,102,445.67

Taxes and surcharges

567,528.04

423,070.27

Selling and marketing expenses

1,790,700.15

1,414,210.51

Administration expenses

20,137,217.46

12,897,768.77

Research and development

expenses

3,091,008.59

5,883,412.68

Finance expenses

-67,971,575.70

-45,241.27

Including: Interest expense

35,500.98

80,365.17

Interest income

136,088.15

123,547.90

Add: Other income

1,255,969.02

3,485,712.94

Investment income

("-" indicating losses)

-8,212,868.51

1,417,202.05

Including: Gains from

investments in associates and

joint ventures

Derecognition of income from

financial assets measured at

amortised cost

Gains from net exposure to

hedging ("-" indicating losses)

Gains from changes in fair

value ("-" indicating losses)

-359,156.16

-484,261.75

Credit impairment losses ("-"

indicating losses)

-37,874.82

-365,606.53

Assets impairment losses ("-"

indicating losses)

9,777,104.64

-606,003.45

Gains from disposal of assets

("-" indicating losses)

-0.60

- 23 -

First Quarter of

First Quarter of

Item

2021

2020

II. Operating profit ("-" indicating

losses)

66,215,575.82

1,278,821.79

Add: Non-operating income

1,905.00

240.00

Less: Non-operating expenses

1,246,320.75

1,970.77

III. Profit before income tax

("-" indicating total loss)

64,971,160.07

1,277,091.02

Less: Income tax expenses

8,910,336.98

342,635.93

IV. Net profits ("-" indicating net loss)

56,060,823.09

934,455.09

(I) Net profit from continuing

operations ("-" indicating net loss)

56,060,823.09

934,455.09

(II)Net profit from discontinued

operations ("-" indicating net loss)

V. Other comprehensive income (net of

tax)

-32,300,000.00

(I) Other comprehensive income that

will not be reclassified to profit or

loss

-32,300,000.00

1. Changes in re-measurement of

defined benefit plans

2. Other comprehensive income

that will not be transferred to

profit or loss accounted for using

equity method

3. Changes in fair value of

investments in other equity

instruments

-32,300,000.00

4. Changes in fair value of the

company's own credit risk

- 24 -

First Quarter of

First Quarter of

Item

2021

2020

(II) Other comprehensive income that

will be reclassified to profit or

loss

1.

Other comprehensive income

that will be transferred to profit

or loss accounted for using

equity method

2.

Changes in fair value of other

debt investments

3.

Financial assets reclassified to

other comprehensive income

4.

Credit impairment allowance of

other debt investments

5.

Cash flow hedging reserve

6.

Exchange difference on

translation of foreign financial

statements

7.

Others

VI. Total comprehensive income

23,760,823.09

934,455.09

VII. Earnings per share:

(I) Basic earnings per share (RMB

per share)

(II) Diluted earnings per share (RMB

per share)

Director of

Legal Representative:

Chief Financial Officer: the Accounting Department:

Feng Yuxia

Yu Aishui

Yu Aishui

- 25 -

Consolidated Cash Flow Statement

January to March 2021

Prepared by: Joinn Laboratories (China) Co., Ltd.

Unit: RMB

Currency: RMB Type of audit: Unaudited

First quarter of

First quarter of

Item

2021

2020

I. Cash flows from operating

activities:

Cash received from the sale of goods

and rendering of services

334,525,902.11

232,670,305.50

Net increase in deposits from

customers and placements from

bank and other financial institutions

Net increase in borrowings from

central bank

Net increase in borrowings from

other financial institutions

Cash received from premiums of

original insurance contracts

Net cash received from reinsurance

operations

Net increase in policyholders'

deposits and investments

Cash received from interest, handling

charges and commission

Net increase in loans from banks and

other financial institutions

Net increase in capital for repurchase

Net cash received from securities

trading agency services

Refund of taxes and surcharges

Cash received from other operating

activities

3,462,521.84

2,732,314.55

Sub-total of cash inflow from

operating activities

337,988,423.95

235,402,620.05

Cash paid for goods purchased and

service rendered

145,523,146.29

75,601,523.86

Net increase in loans and advances to

customers

Net increase in placements with

central bank and other financial

institutions

- 26 -

First quarter of

First quarter of

Item

2021

2020

Cash paid for claims on original

insurance contracts

Net increase in loans to banks and

other financial institutions

Cash paid for interest, handling

charges and commission

Cash paid for policyholders' dividend

Cash paid to and on behalf employees

99,499,941.50

87,788,130.10

Taxes paid

27,767,984.36

17,360,247.52

Cash paid for other operating

activities

30,715,269.04

20,337,535.13

Subtotal of cash outflow from

operating activities

303,506,341.19

201,087,436.61

Net cash flow from operating

activities

34,482,082.76

34,315,183.44

II. Cash flow from investing activities:

Cash received from disposal of

investments

95,000,000.00

200,633,640.41

Cash received from returns on

investment

1,787,131.49

442,671.22

Net cash received from disposal of

fixed assets, intangible assets and

other long-term assets

13,180.00

1,000.00

Net cash received from disposal of

subsidiaries and other business

entities

Cash received from other investing

activities

Subtotal of cash inflow from

investing activities

96,800,311.49

201,077,311.63

Cash paid to acquire fixed assets,

intangible assets and other long-

term assets

45,486,809.33

27,319,871.48

Cash paid to acquire investments

118,000,000.00

203,494,450.00

Net increase in pledged loans

Net cash paid for acquisition of

subsidiaries and other business

entities

Cash paid for other investing

activities

- 27 -

First quarter of

First quarter of

Item

2021

2020

Subtotal of cash outflow from

investing activities

163,486,809.33

230,814,321.48

Net cash flow from investing

activities

-66,686,497.84

-29,737,009.85

III.Cash flow from financing activities:

Cash received from capital

contributions

5,318,194,000.94

Including: Cash received from

capital contribution by

minority shareholders of

subsidiaries

Cash received from borrowings

24,073,120.00

Cash received relating to other

financing activities

Sub-total of cash inflow from

financing activities

5,318,194,000.94

24,073,120.00

Cash repayments of borrowings

759,417.16

22,136,272.58

Cash payments for distribution

of dividends, profits or interest

expenses

116,527.70

334,689.14

Including: Dividends and profits paid

by subsidiaries to non-

controlling interests

Cash payments relating to other

financing activities

4,874,701.20

Sub-total of cash outflow from

financing activities

5,750,646.06

22,470,961.72

Net cash flow from financing

activities

5,312,443,354.88

1,602,158.28

IV.Effect of foreign exchange

rate changes on cash and cash

equivalents

68,794,995.96

1,650,078.20

V. Net increase in cash and cash

equivalents

5,349,033,935.76

7,830,410.07

Add: Cash and cash equivalents at the

beginning of the period

305,043,920.05

175,957,784.22

VI.Cash and cash equivalents at the

end of the period

5,654,077,855.81

183,788,194.29

Director of

Legal Representative:

Chief Financial Officer: the Accounting Department:

Feng Yuxia

Yu Aishui

Yu Aishui

- 28 -

Cash Flow Statement of the Parent Company

January to March 2021

Prepared by: Joinn Laboratories (China) Co., Ltd.

Unit: RMB

Currency: RMB Type of audit: Unaudited

First quarter of

First quarter of

Item

2021

2020

I. Cash flow from operating activities:

Cash received from sale of goods or

rendering of services

76,503,028.57

57,985,149.58

Refund of taxes and surcharges

Cash received relating to other

operating activities

50,807,677.80

10,390,350.91

Sub-total of cash inflow from

operating activities

127,310,706.37

68,375,500.49

Cash paid for purchasing goods and

receiving services

48,742,359.11

24,949,461.07

Cash paid to and on behalf of

employees

28,762,505.41

31,000,317.07

Payments of taxes and surcharges

2,096,937.96

5,363,174.46

Cash paid relating to other operating

activities

44,761,446.97

4,914,147.78

Sub-total of cash outflow from

operating activities

124,363,249.45

66,227,100.38

Net cash flow from operating

activities

2,947,456.92

2,148,400.11

II. Cash flow from investing activities:

Cash received from disposal of

investments

95,000,000.00

190,633,640.41

Cash received from returns on

investments

1,787,131.49

410,821.91

Net cash received from disposal of

fixed assets, intangible assets and

other long-term assets

280.00

Net cash received from disposal of

subsidiaries and other business

entities

Cash received relating to other

investing activities

Sub-total of cash inflow from

investing activities

96,787,411.49

191,044,462.32

Cash paid to acquire fixed assets,

intangible assets and other long-

term assets

3,756,772.00

6,450,277.70

- 29 -

First quarter of

First quarter of

Item

2021

2020

Cash paid to acquire investments

112,000,000.00

193,000,000.00

Net cash paid to acquire subsidiaries

and other business entities

Cash paid relating to other investing

activities

Sub-total of cash outflow from

investing activities

115,756,772.00

199,450,277.70

Net cash flow from investing

activities

-18,969,360.51

-8,405,815.38

III.Cash flow from financing activities:

Cash received from capital

contributions

5,318,194,000.94

Cash received from borrowings

18,482,000.00

Cash received relating to other

financing activities

Sub-total of cash inflow from

financing activities

5,318,194,000.94

18,482,000.00

Cash repayments of borrowings

18,482,000.00

Cash payments for distribution

of dividends, profits or interest

expenses

80,365.17

Cash paid relating to other financing

activities

4,874,701.20

Sub-total of cash outflow from

financing activities

4,874,701.20

18,562,365.17

Net cash flow from financing

activities

5,313,319,299.74

-80,365.17

IV.Effect of foreign exchange

rate changes on cash and cash

equivalents

68,059,644.37

49,037.91

V. Net increase in cash and cash

equivalents

5,365,357,040.52

-6,288,742.53

Add: Cash and cash equivalents at

the beginning of the period

49,939,882.78

39,455,567.02

VI.Cash and cash equivalents at the

end of the period

5,415,296,923.30

33,166,824.49

Director of

Legal Representative:

Chief Financial Officer: the Accounting Department:

Feng Yuxia

Yu Aishui

Yu Aishui

- 30 -

4.2 Adjustments on the financial statements at the beginning of the first year of adopting new leasing standards since 2021

  • Applicable □ Not applicable

Consolidated Balance Sheet

Unit: RMB

Currency: RMB

As at

As at

Item

December 31, 2020

January 1, 2021

Adjustment

Current assets:

Cash at bank and on hand

308,689,959.55

308,689,959.55

Balances with clearing

companies

Placements with banks and

other financial institutions

Financial assets held for

238,902,999.99

238,902,999.99

trading

Derivative financial assets

Bills receivables

2,175,000.00

2,175,000.00

Account receivables

88,866,136.10

88,866,136.10

Receivables financing

Prepayments

49,509,582.85

49,509,582.85

Premium receivables

Reinsurance account

receivables

Deposit receivables from

reinsurance contracts

Other receivables

8,765,341.77

8,765,341.77

Including: Interest

receivables

Dividend

receivables

Financial assets purchased

under agreements to resell

Inventories

406,214,711.26

406,214,711.26

Contract assets

66,812,242.99

66,812,242.99

Assets held-for-sale

Non-current assets due

within one year

- 31 -

As at

As at

Item

December 31, 2020

January 1, 2021

Adjustment

Other current assets

12,974,960.25

12,750,717.63

-224,242.62

Total current assets

1,182,910,934.76

1,182,686,692.14

-224,242.62

Non-current assets:

Loans and advances to

customers

Debt investment

Other debt investment

Long-term receivables

Long-term equity

investments

Investments in other equity

64,444,809.52

64,444,809.52

instruments

Other non-current financial

assets

Investment properties

Fixed assets

445,555,655.12

445,555,655.12

Construction in progress

48,633,480.15

48,633,480.15

Biological assets for

19,433,780.68

19,433,780.68

breeding

Oil and gas assets

Right-of-use assets

69,143,724.01

69,143,724.01

Intangible assets

123,631,240.12

123,631,240.12

Development expenses

Goodwill

125,295,803.39

125,295,803.39

Long-term deferred

26,421,330.44

22,581,205.46

-3,840,124.98

expenditures

Deferred tax assets

35,261,614.74

35,261,614.74

Other non-current assets

36,232,987.14

36,232,987.14

Total non-current assets

924,910,701.30

990,214,300.33

65,303,599.03

Total assets

2,107,821,636.06

2,172,900,992.47

65,079,356.41

Current liabilities:

Short-term borrowings

Borrowings from central

bank

Placement from banks and

other financial institutions

Financial liabilities held for

trading

- 32 -

As at

As at

Item

December 31, 2020

January 1, 2021

Adjustment

Derivative financial

liabilities

Bills payables

Account payables

60,285,553.10

60,285,553.10

Receipts in advance

1,570,000.00

1,570,000.00

Contract liabilities

583,537,351.54

583,537,351.54

Financial assets sold under

agreements to repurchase

Deposits from customers and

banks

Customer deposits for

securities trading

Customer deposits for

securities underwriting

Employee benefit payables

49,700,312.39

49,700,312.39

Tax payables

25,600,650.35

25,600,650.35

Other payables

32,997,002.18

32,742,752.18

-254,250.00

Including:

Interest

payables

Dividend

payables

Handling charges and

commission payable

Reinsurance account

payables

Liabilities held-for-sale

Non-current liabilities due

3,080,988.42

17,600,778.09

14,519,789.67

within one year

Other current liabilities

3,270,304.53

3,270,304.53

Total current liabilities

760,042,162.51

774,307,702.18

14,265,539.67

Non-current liabilities:

Deposits for insurance

contracts

Long-term borrowings

21,375,166.75

21,375,166.75

Debenture payables

Including:

Preference

shares

Perpetual bonds

- 33 -

As at

As at

Item

December 31, 2020

January 1, 2021

Adjustment

Lease liabilities

53,170,080.61

53,170,080.61

Long-term payables

Long-term payroll payable

Projected liabilities

Deferred income

67,040,785.16

67,040,785.16

Deferred tax liabilities

35,199,365.36

35,199,365.36

Other non-current liabilities

Total non-current

123,615,317.27

176,785,397.88

53,170,080.61

liabilities

Total liabilities

883,657,479.78

951,093,100.06

67,435,620.28

Owners' equity (or

shareholders' equity):

Paid up capital (or share

227,454,729.00

227,454,729.00

capital)

Other equity instruments

Including: Preference

shares

Perpetual bonds

Capital reserves

249,804,268.45

249,804,268.45

Less: Treasury shares

9,915,527.00

9,915,527.00

Other comprehensive income

29,063,134.69

29,220,532.44

157,397.75

Special reserve

Surplus reserve

59,290,828.07

59,290,828.07

General risks reserve

Retained earnings

669,201,659.08

666,687,997.46

-2,513,661.62

Total owners' equity (or

1,224,899,092.29

1,222,542,828.42

-2,356,263.87

shareholders' equity)

attributable to the parent

company

Non-controlling interests

-734,936.01

-734,936.01

Total owners' equity (or

1,224,164,156.28

1,221,807,892.41

-2,356,263.87

shareholders' equity)

Total liabilities and

2,107,821,636.06

2,172,900,992.47

65,079,356.41

owners' equity (or

shareholders' equity)

- 34 -

Explanation of adjustment of each item:

  • Applicable □ Not applicable

In December 2018, the Ministry of Finance of the People's Republic of China issued the Circular regarding Amendments on the PRC Accounting Standards for Business Enterprises No. 21 - Leases (Cai Kuai [2018] No. 35). Upon approval by the Board, the Company announced the adoption of above revised accounting standards in the Group commencing on January 1, 2021. Due to cumulative effect of the adoption, the Group adjusted the opening balance of retained earnings and the amounts of other related items in the financial statements at the beginning of the year (in which this standard was initially adopted). The data of comparable period shall not be adjusted.

Balance Sheet of the Parent Company

Unit: RMB

Currency: RMB

Item

As at

As at

Adjustment

December 31, 2020

January 1, 2021

Current assets:

Cash at bank and on hand

49,939,882.78

49,939,882.78

Financial assets held for

208,003,904.10

208,003,904.10

trading

Derivative financial assets

Bills receivables

Account receivables

7,980,312.02

7,980,312.02

Receivables financing

Prepayments

27,191,935.98

27,191,935.98

Other receivables

55,977,804.58

55,977,804.58

Including: Interest

receivables

Dividend

receivables

Inventories

103,417,687.78

103,417,687.78

Contract assets

34,223,306.49

34,223,306.49

Assets held-for-sale

Non-current assets due within

one year

Other current assets

3,927,708.06

3,927,708.06

Total current assets

490,662,541.79

490,662,541.79

Non-current assets:

Debt investments

Other debt investments

Long-term receivables

- 35 -

Item

As at

As at

Adjustment

December 31, 2020

January 1, 2021

Long-term equity investments

549,277,848.74

549,277,848.74

Investments in other equity

64,444,809.52

64,444,809.52

instruments

Other non-current financial

assets

Investment properties

Fixed assets

120,373,701.14

120,373,701.14

Construction in progress

2,137,481.93

2,137,481.93

Biological assets for breeding

Oil and gas assets

Right-of-use assets

2,776,891.12

2,776,891.12

Intangible assets

17,856,922.01

17,856,922.01

Development expenses

Goodwill

Long-term deferred

3,672,458.65

3,672,458.65

expenditures

Deferred tax assets

10,414,065.73

10,414,065.73

Other non-current assets

3,923,902.76

3,923,902.76

Total non-current assets

772,101,190.48

774,878,081.60

2,776,891.12

Total assets

1,262,763,732.27

1,265,540,623.39

2,776,891.12

Current liabilities:

Short-term borrowings

Financial liabilities held for

trading

Derivative financial liabilities

Bills payables

Account payables

30,898,749.24

30,898,749.24

Receipts in advance

Contract liabilities

194,127,498.08

194,127,498.08

Employee benefit payables

16,783,931.66

16,783,931.66

Tax payables

1,201,325.41

1,201,325.41

Other payables

16,168,322.16

16,168,322.16

Including: Interest payables

Dividend

payables

Liabilities held-for-sale

- 36 -

Item

As at

As at

Adjustment

December 31, 2020

January 1, 2021

Non-current liabilities due

1,362,778.04

1,362,778.04

within one year

Other current liabilities

1,452,133.47

1,452,133.47

Total current liabilities

260,631,960.02

261,994,738.06

1,362,778.04

Non-current liabilities:

Long-term borrowings

Debenture payables

Including: Preference shares

Perpetual bonds

Lease liabilities

1,773,784.94

1,773,784.94

Long-term payables

Long-term payroll payables

Projected liabilities

Deferred income

14,107,308.34

14,107,308.34

Deferred tax liabilities

13,885,085.02

13,885,085.02

Other non-current liabilities

Total non-current liabilities

27,992,393.36

29,766,178.30

1,773,784.94

Total liabilities

288,624,353.38

291,760,916.36

3,136,562.98

Owners' equity (shareholders'

equity):

Paid-in capital (or share

227,454,729.00

227,454,729.00

capital)

Other equity investments

Including: Preference shares

Perpetual bonds

Capital reserves

240,609,043.62

240,609,043.62

Less: Treasury shares

9,915,527.00

9,915,527.00

Other comprehensive income

44,578,088.09

44,578,088.09

Special reserve

Surplus reserve

59,290,828.07

59,290,828.07

Retained earnings

412,122,217.11

411,762,545.25

-359,671.86

Total Owners' equity (or

974,139,378.89

973,779,707.03

-359,671.86

shareholders' equity)

Total liabilities and

1,262,763,732.27

1,265,540,623.39

2,776,891.12

owners' equity (or

shareholders' equity)

- 37 -

Explanation of adjustment of each item:

  • Applicable □ Not applicable

In December 2018, the Ministry of Finance of the People's Republic of China issued the Circular regarding Amendments on the PRC Accounting Standards for Business Enterprises No. 21 - Leases (Cai Kuai [2018] No. 35). Upon approval by the Board, the Company announced the adoption of above revised accounting standards in the Group commencing on January 1, 2021. Due to cumulative effect of the adoption, the Group adjusted the opening balance of retained earnings and the amounts of other related items in the financial statements at the beginning of the year (in which this standard was initially adopted). The data of comparable period shall not be adjusted.

  1. Explanation of first adoption of new leasing standards and comparative data of retrospective adjustment of the previous reporting period since 2021
    • Applicable ✓ Not applicable
  3. Auditor's report
    • Applicable ✓ Not applicable

- 38 -

Attachments

  • Original document
  • Permalink

Disclaimer

Joinn Laboratories China Co. Ltd. published this content on 30 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 April 2021 00:09:03 UTC.